COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk A/S - Share repurchase programme

17/07/2017 - 13:56

Bagsværd, Denmark, 17 July 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]

MITHRA SUBMITS MYRING(TM) FOR EUROPEAN MARKETING APPROVAL

17/07/2017 - 07:30

PRESS RELEASE mithra submits MYRING(TM) For EUROpean Marketing approval Myring(TM) regulatory approvals in Europe and the US expected in 2018 Regulatory s ubmission follows recent European GMP approval for Myring(TM) [...]

ABLYNX PROPOSES APPOINTMENT OF MRS HILDE WINDELS AS A NEW INDEPENDENT DIRECTOR

17/07/2017 - 07:00

GHENT, Belgium, 17 July 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that Hilde Windels will be nominated as an Independent Non-Executive Director at the Company's forthcoming Special General [...]

L'Association internationale pour l'étude du cancer du poumon annonce la 18e Conférence mondiale IASLC sur le cancer du poumon

14/07/2017 - 20:00

La seule conférence mondiale axée uniquement sur le cancer du poumon regroupera des milliers de personnes au Japon DENVER, le 14 juillet 2017 (GLOBE NEWSWIRE) - L'Association internationale pour l'étude du cancer du [...]

Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis

14/07/2017 - 19:21

5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis[1] Data planned to be presented at a key medical congress [...]

IBA SA : IBA - NOTIFICATION DE TRANSPARENCE

14/07/2017 - 17:50

IBA - NOTIFICATION DE TRANSPARENCE Louvain-la-Neuve, Belgique, 14 juillet 2017, 17h40 - IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce [...]

IBA SA : IBA - TRANSPARENCY NOTIFICATION

14/07/2017 - 17:50

IBA - TRANSPARENCY NOTIFICATION Louvain-la-Neuve, Belgium, July 14, 2017, 5.40 p.m. - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that [...]

Targovax ASA: Preliminary result of the subsequent offering

14/07/2017 - 17:24

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE [...]

Crown Bioscience enrichit son portefeuille de sciences de la vie

14/07/2017 - 12:45

SANTA CLARA, Californie, le 14 juillet 2017 (GLOBE NEWSWIRE) - Crown Bioscience , filiale en propriété exclusive de Crown Bioscience International (TWSE : symbole boursier 6554) et société internationale de services de [...]

Enzymatica recruits Chief Operating Officer

14/07/2017 - 11:30

Press release Lund, 14 July, 2017 Enzymatica recruits Chief Operating Officer Enzymatica has recruited Johan Lindvall as Chief Operating Officer and Executive Vice President. He will be responsible for Enzymatica's [...]

Targovax ASA: Last day of the subscription period in the subsequent offering

14/07/2017 - 07:15

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE [...]

Solon Eiendom ASA : Primary insider notification

13/07/2017 - 23:08

(Oslo, Norway, 13 July 2017) Solon Eiendom ASA Board Member Tore Aksel Voldberg (through his wholly owned company Skøien AS) has today bought 25,000 shares in Solon Eiendom ASA at a price of NOK 18,0843. Following this [...]

FOR SALE: State-of-the-Art cGMP-Qualified Solid Dosage Development and Manufacturing Facility

13/07/2017 - 20:52

The 100,000+ sq.-ft. facility is located on Long Island, less than 50 miles from New York City. COMMACK, NY, July 13, 2017 (GLOBE NEWSWIRE) -- A spacious, technologically advanced facility, conveniently located within [...]

GENFIT - The NASH Education ProgramTM annonce le lancement de la première Journée Internationale d'Information sur la NASH, le 12 juin 2018

13/07/2017 - 19:19

GENFIT - The NASH Education Program TM annonce le lancement de la première Journée Internationale d'Information sur la NASH, le 12 juin 2018 Journée internationale de sensibilisation à la NASH, pathologie silencieuse [...]

GENFIT - The NASH Education ProgramTM announces the launch of the first International NASH Information Day on June 12, 2018: Save the date!

13/07/2017 - 19:19

GENFIT - The NASH Education Program TM announces the launch of the first International NASH Information Day on June 12, 2018: Save the date! A day to raise awareness around NASH, a widespread but little known disease, [...]

The International Association for the Study of Lung Cancer Announces the IASLC 18th World Conference on Lung Cancer

13/07/2017 - 18:22

The only global meeting focused solely on lung cancer will convene thousands in Japan DENVER, July 13, 2017 (GLOBE NEWSWIRE) -- The International Association for the Study of Lung Cancer (IASLC) announced today that the [...]

Oriola Corporation revises guidance for continuing operations adjusted operating profit

13/07/2017 - 18:01

Oriola Corporation Stock Exchange Release 13 July 2017 at 19.00 Oriola Corporation revises guidance for continuing operations adjusted operating profit Despite the recent improvements in the performance of the Consumer [...]

Innate Pharma: Émission de 3 343 748 actions ordinaires au bénéfice de Novo Nordisk A/S en rémunération des droits sur l'anti-C5aR

13/07/2017 - 17:53

ÉMISSION PAR INNATE PHARMA DE 3 343 748 ACTIONS ORDINAIRES AU BÉNÉFICE DE Novo Nordisk A/S EN RÉMUNERATION DES Droits sur L'ANTI-C5 aR L'acquisition de l'anti-C5aR, un anticorps « first-in-class » au stade clinique, [...]

Issuance by Innate Pharma of 3,343,748 ordinary shares to Novo Nordisk A/S in consideration for rights in anti-C5aR

13/07/2017 - 17:53

Issuance by INNATE PHARMA of 3,343,748 ordinary shares to Novo Nordisk A/S in consideration for RIghts in ANTI-C5 aR The acquisition of the anti-C5aR, a first-in-class clinical-stage antibody, announced on June 2, 2017 [...]